HSS Journal

, Volume 8, Issue 1, pp 64–65

Patient Evaluation and OA Study Design: OARSI/Biomarker Qualification

HSS Osteoarthritis Symposium: Frontiers in OA


biomarkers osteoarthritis FDA qualification drug development tools 


  1. 1.
    Colman, E. G. 2003. The Food and Drug Administration's Osteoporosis Guidance Document: past, present, and future. J Bone Miner Res, 18, 1125–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Conaghan, P. G., Hunter, D. J., Maillefert, J. F., Reichmann, W. M. & Losina, E. 2011. Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis Cartilage, 19, 606–10.PubMedCrossRefGoogle Scholar
  3. 3.
    FDA, F. A. D. A. 2010. Guidance for Industry: Qualification Process for Drug Development Tools. October.Google Scholar
  4. 4.
    Kraus, V. B., Burnett, B., Coindreau, J., Cottrell, S., Eyre, D., Gendreau, M., Gardiner, J., Garnero, P., Hardin, J., Henrotin, Y., Heinegard, D., Ko, A., Lohmander, S., Matthews, G., Menetski, J., Moskowitz, R., Persiani, S., Poole, R., Rousseau, J. C. & Todman, M. 2011. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage.Google Scholar
  5. 5.
    Wagner, J. A., Williams, S. A. & Webster, C. J. 2007. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther, 81, 104–7.PubMedCrossRefGoogle Scholar

Copyright information

© Hospital for Special Surgery 2011

Authors and Affiliations

  1. 1.Duke University Medical CenterDurhamUSA

Personalised recommendations